LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | JW-7-24-1 | 0.37 | uM | LJP6 | 72 | hr | 868 | 2426 | 3486 | 0.6959 | 0.5950 |
MDA-MB-231 | Lapatinib | 0.37 | uM | LJP6 | 72 | hr | 868 | 3351 | 3486 | 0.9614 | 0.9485 |
MDA-MB-231 | LDN-193189 | 0.37 | uM | LJP5 | 72 | hr | 868 | 3428 | 3486 | 0.9834 | 0.9778 |
MDA-MB-231 | Linifanib | 0.37 | uM | LJP6 | 72 | hr | 868 | 4037 | 3486 | 1.1580 | 1.2104 |
MDA-MB-231 | Linsitinib | 0.37 | uM | LJP5 | 72 | hr | 868 | 2875 | 3486 | 0.8246 | 0.7665 |
MDA-MB-231 | Mitoxantrone | 0.37 | uM | LJP5 | 72 | hr | 868 | 810 | 3486 | 0.2325 | -0.0219 |
MDA-MB-231 | Mitoxantrone | 0.37 | uM | LJP6 | 72 | hr | 868 | 827 | 3486 | 0.2374 | -0.0155 |
MDA-MB-231 | MK2206 | 0.37 | uM | LJP6 | 72 | hr | 868 | 2762 | 3486 | 0.7923 | 0.7235 |
MDA-MB-231 | Neratinib | 0.37 | uM | LJP5 | 72 | hr | 868 | 2194 | 3486 | 0.6293 | 0.5064 |
MDA-MB-231 | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 868 | 2617 | 3486 | 0.7506 | 0.6680 |
MDA-MB-231 | Nintedanib | 0.37 | uM | LJP6 | 72 | hr | 868 | 3503 | 3486 | 1.0049 | 1.0065 |
MDA-MB-231 | NU7441 | 0.37 | uM | LJP5 | 72 | hr | 868 | 2800 | 3486 | 0.8032 | 0.7380 |
MDA-MB-231 | Dactolisib | 0.37 | uM | LJP5 | 72 | hr | 868 | 1589 | 3486 | 0.4559 | 0.2755 |
MDA-MB-231 | NVP-TAE684 | 0.37 | uM | LJP6 | 72 | hr | 868 | 2590 | 3486 | 0.7430 | 0.6578 |
MDA-MB-231 | Palbociclib | 0.37 | uM | LJP6 | 72 | hr | 868 | 1974 | 3486 | 0.5664 | 0.4226 |
MDA-MB-231 | PD0325901 | 0.37 | uM | LJP5 | 72 | hr | 868 | 1473 | 3486 | 0.4225 | 0.2310 |
MDA-MB-231 | PD0325901 | 0.37 | uM | LJP6 | 72 | hr | 868 | 1384 | 3486 | 0.3972 | 0.1973 |
MDA-MB-231 | PD173074 | 0.37 | uM | LJP6 | 72 | hr | 868 | 3593 | 3486 | 1.0306 | 1.0407 |
MDA-MB-231 | PD184352 | 0.37 | uM | LJP5 | 72 | hr | 868 | 2608 | 3486 | 0.7481 | 0.6645 |
MDA-MB-231 | Pelitinib | 0.37 | uM | LJP5 | 72 | hr | 868 | 2867 | 3486 | 0.8225 | 0.7637 |
MDA-MB-231 | PF431396 | 0.37 | uM | LJP5 | 72 | hr | 868 | 2233 | 3486 | 0.6405 | 0.5213 |
MDA-MB-231 | PF477736 | 0.37 | uM | LJP5 | 72 | hr | 868 | 2622 | 3486 | 0.7521 | 0.6699 |
MDA-MB-231 | PF562271 | 0.37 | uM | LJP6 | 72 | hr | 868 | 2810 | 3486 | 0.8061 | 0.7418 |
MDA-MB-231 | PHA-665752 | 0.37 | uM | LJP5 | 72 | hr | 868 | 3640 | 3486 | 1.0441 | 1.0587 |
MDA-MB-231 | PHA-793887 | 0.37 | uM | LJP6 | 72 | hr | 868 | 985 | 3486 | 0.2827 | 0.0449 |